KDR and Bruton-type agammaglobulinemia: Inhibitors of hypoxia-inducible factor (IDF-11774), MCL-1 (S63845, AZD-5991, pyridoclax, and S-64315), ribonucleotide reductase (imexon), FASN (JNJ-54302833), WNT signaling (CCT251545), STAT/STAT3 (CPD-401), and CHK (rabusertib) were among the top 10 drugs in clinical trial that may work in patients with high YAP1 expression, whereas inhibitors of EGFR (TAS6417), Bruton’s agammaglobulinemia tyrosine kinase (BTK) (spebrutinib), SYK (entospletinib), RET (Blu667), VEGFR2 (ENMD-2076, P-529), and αvβ3 integrin (MK-0429, cilengitide) may not work (Figure 7).